New Psychoactive Substance-Global Market Status and Trend Report 2016-2026
Report Summary
New Psychoactive Substance-Global Market Status and Trend Report 2016-2026 offers a comprehensive analysis on New Psychoactive Substance industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of New Psychoactive Substance 2016-2021, and development forecast 2022-2026
Main manufacturers/suppliers of New Psychoactive Substance worldwide, with company and product introduction, position in the New Psychoactive Substance market
Market status and development trend of New Psychoactive Substance by types and applications
Cost and profit status of New Psychoactive Substance, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium New Psychoactive Substance market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the New Psychoactive Substance industry.
The report segments the global New Psychoactive Substance market as:
Global New Psychoactive Substance Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):
North America
Europe
China
Japan
Rest APAC
Latin America
Global New Psychoactive Substance Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):
Stimulants
Cannabinoids
Hallucinogens
Depressants
Global New Psychoactive Substance Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis)
Cancer
Neuropathic Disorders
Spasticity
Others
Global New Psychoactive Substance Market: Manufacturers Segment Analysis (Company and Product introduction, New Psychoactive Substance Sales Volume, Revenue, Price and Gross Margin):
Zynerba Pharmaceuticals
GW Pharmaceuticals
Teewinot Life Sciences
AusCann
Cannabics Pharmaceuticals
Tilray
Cyrelian
Anandia Laboratories
InMed Pharmaceuticals
Renew Biopharma
Cronos Group
ICC International Cannabis
Biotii Technologies
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
New Psychoactive Substance-Global Market Status and Trend Report 2016-2026 offers a comprehensive analysis on New Psychoactive Substance industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of New Psychoactive Substance 2016-2021, and development forecast 2022-2026
Main manufacturers/suppliers of New Psychoactive Substance worldwide, with company and product introduction, position in the New Psychoactive Substance market
Market status and development trend of New Psychoactive Substance by types and applications
Cost and profit status of New Psychoactive Substance, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium New Psychoactive Substance market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the New Psychoactive Substance industry.
The report segments the global New Psychoactive Substance market as:
Global New Psychoactive Substance Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):
North America
Europe
China
Japan
Rest APAC
Latin America
Global New Psychoactive Substance Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):
Stimulants
Cannabinoids
Hallucinogens
Depressants
Global New Psychoactive Substance Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis)
Cancer
Neuropathic Disorders
Spasticity
Others
Global New Psychoactive Substance Market: Manufacturers Segment Analysis (Company and Product introduction, New Psychoactive Substance Sales Volume, Revenue, Price and Gross Margin):
Zynerba Pharmaceuticals
GW Pharmaceuticals
Teewinot Life Sciences
AusCann
Cannabics Pharmaceuticals
Tilray
Cyrelian
Anandia Laboratories
InMed Pharmaceuticals
Renew Biopharma
Cronos Group
ICC International Cannabis
Biotii Technologies
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF NEW PSYCHOACTIVE SUBSTANCE
1.1 Definition of New Psychoactive Substance in This Report
1.2 Commercial Types of New Psychoactive Substance
1.2.1 Stimulants
1.2.2 Cannabinoids
1.2.3 Hallucinogens
1.2.4 Depressants
1.3 Downstream Application of New Psychoactive Substance
1.3.1 Cancer
1.3.2 Neuropathic Disorders
1.3.3 Spasticity
1.3.4 Others
1.4 Development History of New Psychoactive Substance
1.5 Market Status and Trend of New Psychoactive Substance 2016-2026
1.5.1 Global New Psychoactive Substance Market Status and Trend 2016-2026
1.5.2 Regional New Psychoactive Substance Market Status and Trend 2016-2026
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of New Psychoactive Substance 2016-2021
2.2 Production Market of New Psychoactive Substance by Regions
2.2.1 Production Volume of New Psychoactive Substance by Regions
2.2.2 Production Value of New Psychoactive Substance by Regions
2.3 Demand Market of New Psychoactive Substance by Regions
2.4 Production and Demand Status of New Psychoactive Substance by Regions
2.4.1 Production and Demand Status of New Psychoactive Substance by Regions 2016-2021
2.4.2 Import and Export Status of New Psychoactive Substance by Regions 2016-2021
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of New Psychoactive Substance by Types
3.2 Production Value of New Psychoactive Substance by Types
3.3 Market Forecast of New Psychoactive Substance by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of New Psychoactive Substance by Downstream Industry
4.2 Market Forecast of New Psychoactive Substance by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE
5.1 Global Economy Situation and Trend Overview
5.2 New Psychoactive Substance Downstream Industry Situation and Trend Overview
CHAPTER 6 NEW PSYCHOACTIVE SUBSTANCE MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of New Psychoactive Substance by Major Manufacturers
6.2 Production Value of New Psychoactive Substance by Major Manufacturers
6.3 Basic Information of New Psychoactive Substance by Major Manufacturers
6.3.1 Headquarters Location and Established Time of New Psychoactive Substance Major Manufacturer
6.3.2 Employees and Revenue Level of New Psychoactive Substance Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 NEW PSYCHOACTIVE SUBSTANCE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Zynerba Pharmaceuticals
7.1.1 Company profile
7.1.2 Representative New Psychoactive Substance Product
7.1.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Zynerba Pharmaceuticals
7.2 GW Pharmaceuticals
7.2.1 Company profile
7.2.2 Representative New Psychoactive Substance Product
7.2.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of GW Pharmaceuticals
7.3 Teewinot Life Sciences
7.3.1 Company profile
7.3.2 Representative New Psychoactive Substance Product
7.3.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Teewinot Life Sciences
7.4 AusCann
7.4.1 Company profile
7.4.2 Representative New Psychoactive Substance Product
7.4.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of AusCann
7.5 Cannabics Pharmaceuticals
7.5.1 Company profile
7.5.2 Representative New Psychoactive Substance Product
7.5.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Cannabics Pharmaceuticals
7.6 Tilray
7.6.1 Company profile
7.6.2 Representative New Psychoactive Substance Product
7.6.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Tilray
7.7 Cyrelian
7.7.1 Company profile
7.7.2 Representative New Psychoactive Substance Product
7.7.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Cyrelian
7.8 Anandia Laboratories
7.8.1 Company profile
7.8.2 Representative New Psychoactive Substance Product
7.8.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Anandia Laboratories
7.9 InMed Pharmaceuticals
7.9.1 Company profile
7.9.2 Representative New Psychoactive Substance Product
7.9.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of InMed Pharmaceuticals
7.10 Renew Biopharma
7.10.1 Company profile
7.10.2 Representative New Psychoactive Substance Product
7.10.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Renew Biopharma
7.11 Cronos Group
7.11.1 Company profile
7.11.2 Representative New Psychoactive Substance Product
7.11.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Cronos Group
7.12 ICC International Cannabis
7.12.1 Company profile
7.12.2 Representative New Psychoactive Substance Product
7.12.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of ICC International Cannabis
7.13 Biotii Technologies
7.13.1 Company profile
7.13.2 Representative New Psychoactive Substance Product
7.13.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Biotii Technologies
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE
8.1 Industry Chain of New Psychoactive Substance
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE
9.1 Cost Structure Analysis of New Psychoactive Substance
9.2 Raw Materials Cost Analysis of New Psychoactive Substance
9.3 Labor Cost Analysis of New Psychoactive Substance
9.4 Manufacturing Expenses Analysis of New Psychoactive Substance
CHAPTER 10 MARKETING STATUS ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of New Psychoactive Substance in This Report
1.2 Commercial Types of New Psychoactive Substance
1.2.1 Stimulants
1.2.2 Cannabinoids
1.2.3 Hallucinogens
1.2.4 Depressants
1.3 Downstream Application of New Psychoactive Substance
1.3.1 Cancer
1.3.2 Neuropathic Disorders
1.3.3 Spasticity
1.3.4 Others
1.4 Development History of New Psychoactive Substance
1.5 Market Status and Trend of New Psychoactive Substance 2016-2026
1.5.1 Global New Psychoactive Substance Market Status and Trend 2016-2026
1.5.2 Regional New Psychoactive Substance Market Status and Trend 2016-2026
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of New Psychoactive Substance 2016-2021
2.2 Production Market of New Psychoactive Substance by Regions
2.2.1 Production Volume of New Psychoactive Substance by Regions
2.2.2 Production Value of New Psychoactive Substance by Regions
2.3 Demand Market of New Psychoactive Substance by Regions
2.4 Production and Demand Status of New Psychoactive Substance by Regions
2.4.1 Production and Demand Status of New Psychoactive Substance by Regions 2016-2021
2.4.2 Import and Export Status of New Psychoactive Substance by Regions 2016-2021
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of New Psychoactive Substance by Types
3.2 Production Value of New Psychoactive Substance by Types
3.3 Market Forecast of New Psychoactive Substance by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of New Psychoactive Substance by Downstream Industry
4.2 Market Forecast of New Psychoactive Substance by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE
5.1 Global Economy Situation and Trend Overview
5.2 New Psychoactive Substance Downstream Industry Situation and Trend Overview
CHAPTER 6 NEW PSYCHOACTIVE SUBSTANCE MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of New Psychoactive Substance by Major Manufacturers
6.2 Production Value of New Psychoactive Substance by Major Manufacturers
6.3 Basic Information of New Psychoactive Substance by Major Manufacturers
6.3.1 Headquarters Location and Established Time of New Psychoactive Substance Major Manufacturer
6.3.2 Employees and Revenue Level of New Psychoactive Substance Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 NEW PSYCHOACTIVE SUBSTANCE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Zynerba Pharmaceuticals
7.1.1 Company profile
7.1.2 Representative New Psychoactive Substance Product
7.1.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Zynerba Pharmaceuticals
7.2 GW Pharmaceuticals
7.2.1 Company profile
7.2.2 Representative New Psychoactive Substance Product
7.2.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of GW Pharmaceuticals
7.3 Teewinot Life Sciences
7.3.1 Company profile
7.3.2 Representative New Psychoactive Substance Product
7.3.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Teewinot Life Sciences
7.4 AusCann
7.4.1 Company profile
7.4.2 Representative New Psychoactive Substance Product
7.4.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of AusCann
7.5 Cannabics Pharmaceuticals
7.5.1 Company profile
7.5.2 Representative New Psychoactive Substance Product
7.5.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Cannabics Pharmaceuticals
7.6 Tilray
7.6.1 Company profile
7.6.2 Representative New Psychoactive Substance Product
7.6.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Tilray
7.7 Cyrelian
7.7.1 Company profile
7.7.2 Representative New Psychoactive Substance Product
7.7.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Cyrelian
7.8 Anandia Laboratories
7.8.1 Company profile
7.8.2 Representative New Psychoactive Substance Product
7.8.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Anandia Laboratories
7.9 InMed Pharmaceuticals
7.9.1 Company profile
7.9.2 Representative New Psychoactive Substance Product
7.9.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of InMed Pharmaceuticals
7.10 Renew Biopharma
7.10.1 Company profile
7.10.2 Representative New Psychoactive Substance Product
7.10.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Renew Biopharma
7.11 Cronos Group
7.11.1 Company profile
7.11.2 Representative New Psychoactive Substance Product
7.11.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Cronos Group
7.12 ICC International Cannabis
7.12.1 Company profile
7.12.2 Representative New Psychoactive Substance Product
7.12.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of ICC International Cannabis
7.13 Biotii Technologies
7.13.1 Company profile
7.13.2 Representative New Psychoactive Substance Product
7.13.3 New Psychoactive Substance Sales, Revenue, Price and Gross Margin of Biotii Technologies
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE
8.1 Industry Chain of New Psychoactive Substance
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE
9.1 Cost Structure Analysis of New Psychoactive Substance
9.2 Raw Materials Cost Analysis of New Psychoactive Substance
9.3 Labor Cost Analysis of New Psychoactive Substance
9.4 Manufacturing Expenses Analysis of New Psychoactive Substance
CHAPTER 10 MARKETING STATUS ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCE
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
